Trial Profile

An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fosmanogepix (Primary) ; Fosmanogepix (Primary) ; Caspofungin; Fluconazole
Indications Candidaemia; Invasive candidiasis
Focus Registrational; Therapeutic Use
Acronyms FAST-IC
Sponsors Pfizer

16 Apr 2025 According to a Basilea Pharmaceutica media release, data from this study were presented at at ESCMID Global 2025, the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases, which took place from April 11 to 15, 2025 in Vienna, Austria.
10 Dec 2024 Planned initiation date changed from 30 Nov 2024 to 30 Dec 2024.
13 Nov 2024 Planned initiation date changed from 30 Oct 2024 to 30 Nov 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com